CD 14 — AR226-1068a

EPA administrative record segment: CD-14--AR226-1068a (1,777 documents).

Page 4 of 18 — 1,777 documents
Title / Summary Year AR226 Docket Hash ID Pages
The document is a September 2002 surface water monitoring report for the Washington Works facility and local landfills in West Virginia, focusing on C-8 (PFOA) analytical results. 2002 AR226-1167 NG2LM0Jgd6vradXOrX7w1JV2R 42
The document is a Third Quarter 2002 Surface Water and Groundwater Monitoring Report for the Washington Works Facility and local landfills in Washington, WV, focusing on C-8 (PFOA) analytical results in both surface water and groundwater. 2002 AR226-1168 0gRDG5NqYmLy8xzjnjZLJB6Gm 79
The document is a DuPont report detailing the determination of the ultraviolet spectrum for 8-2 Telomer B Alcohol (C8F17CH2CH2OH), conducted under the Telomer Research Program, with a completion date of July 16, 2002. 2002 AR226-1289 JJoj8kygGjXrE0OBygNnpKv1B 8
The document is a letter from Robert A. Bilott to Mary Dominiak at the EPA, submitting various documents related to PFOA for inclusion in Administrative Record 226, including letters and consent orders involving DuPont and public health concerns in West Virginia. 2002 AR226-1169 4JnbNovJ2G3edBdr0nG547koR 3
The document summarizes a two-generation reproduction study of Ammonium Perfluorooctanoate (APFO) in rats conducted by 3M, indicating that while parental animals showed more severe effects than offspring, there were suggestive reproductive effects such as decreased pup weights and altered estrous cyclicity at a dose of 30 mg/kg/day, leading DuPont to conclude that APFO is not 2002 AR226-1307 jyE0EXBdq7eVXX3mDw4j0OKL2 10
The document is a report on a subchronic toxicity study of 8-2 Telomer B Alcohol conducted by Clariant and E.I. du Pont de Nemours and Company, which evaluated the effects of the substance on male and female rats over a 90-day period. 2002 AR226-1341 OJyao9kr005beJor1j1b5M4pM 8
The document reports on the physical-chemical properties of 8-2 Telomer B alcohol, including its ultraviolet spectrum, vapor pressure, and water solubility, with findings indicating low solubility and specific vapor pressure measurements. 2002 AR226-1347 peKGOk7ME2J6k9azQ9y2qdmnk 1
The document reports on a study conducted by DuPont Central Research & Development that assessed the aqueous stability of 8-2 Telomer B Alcohol (8-2 TBA) under various pH conditions, finding it stable at pH 4, 7, and 9 at 50°C and at pH 1.2 at 37°C. 2002 AR226-1348 OErZRod3X816bOwZGkOn7a9Jp 2
This is an EPA Order on Consent regarding E. I. du Pont de Nemours and Company's Washington Works Facility, addressing the release of ammonium perfluorooctanoate (C-8) into the environment and its detection in local drinking water sources. 2002 AR226-1172 JNR7N3oO0danJB9JEDV8LgbEv 10
The document is a correspondence from Taft, Stettinius & Hollister LLP regarding a Consent Order between the West Virginia Department of Environmental Protection and DuPont related to contamination of drinking water with ammonium perfluorooctanoate (C-8) from DuPont's Washington Works facility. 2002 AR226-1174 vgZj15DVJexeKrgyvwR78qBY 3
This letter from the West Virginia Department of Environmental Protection addresses inquiries from Robert A. Bilott regarding the state's decision not to establish a second laboratory for C8 (PFOA) water testing, affirming reliance on the certified Exygen lab, and discusses representation at an upcoming toxicologists meeting. 2002 AR226-1177 q322n1Dzr3QrgnmJg19oLvzMG 2
The document is a response from the EPA to Robert A. Bilott regarding a consent order with E.I. du Pont de Nemours & Company (DuPont) to address concerns about ammonium perfluorooctanoate (PFOA) contamination in drinking water in Parkersburg, West Virginia, acknowledging that PFOA is not currently regulated under the Safe Drinking Water Act but emphasizing 2002 AR226-1179 jjbxO80Oab40Xe8Y0pvZyg4y 2
This is a cover letter from Taft Stettinius & Hollister LLP, dated May 7, 2002, transmitting Section 6 of DuPont's June 1999 RCRA Facility Investigation Report regarding C-8 screening levels in drinking water to various recipients, including members of the CAT Team and EPA officials. 2002 AR226-1180 YGomRN0XjjR2a5Z9yYmmeYeD 22
This letter from the West Virginia Department of Environmental Protection responds to inquiries from Robert A. Bilott regarding the absence of documents related to the CAT team's position on health protective levels for C-8 (PFOA) prior to their upcoming meeting. 2002 AR226-1181 Em2Xy02Bmq3jQB26ja1bkGkK4 2
This is a letter from Taft, Stettinius & Hollister LLP dated June 10, 2002, regarding the C-8 toxicity assessment under a consent order involving DuPont and the State of West Virginia, addressed to various environmental and legal representatives. 2002 AR226-1182 XOGxwEXdkXge7wYBqmZkREgvy 15
The document is a court injunction order concerning a motion by plaintiffs Jack W. Leach et al. against E.I. Du Pont De Nemours and Company and the West Virginia Department of Environmental Protection, regarding the failure to produce records related to the C-8 investigation, specifically concerning the destruction of documents by Dee Ann Staats, Ph.D. 2002 AR226-1183 9Jnx52xwGV9Mvo0D1jbygGZMV 6
The document is a response from the EPA to Robert A. Bilott regarding his request for informal discussions about the C-8 Assessment of Toxicity Team meeting related to PFOA, indicating that the EPA cannot participate due to limited resources. 2002 AR226-1186 jBDK3rQGeLDy7190vJ0Z8KY65 1
This document discusses the transition of attorney Joe Dawley from representing E.I. duPont de Nemours and Company in C-8 (PFOA) litigation to becoming the General Counsel for the West Virginia Department of Environmental Protection, highlighting concerns about his prior involvement in compliance issues related to the lawsuit. 2002 AR226-1187 Yr3m7KDN3pe3NJXJrwjRN4x9E 13
This letter from Taft, Stettinius & Hollister LLP addresses the West Virginia Department of Environmental Protection's deviation from the Consent Order regarding the assessment of C-8 (PFOA) toxicity issues by the C-8 Assessment of Toxicity Team. 2002 AR226-1188 7Mv6pBBYRrxmeMORe2gJ19BwB 17
The document provides finalized C-8 (PFOA) results for public water supplies sampled along the Ohio River in West Virginia and Ohio, detailing findings from multiple sampling events conducted by DuPont Washington Works. 2002 AR226-1190 xz46bpRV58m16VDkq9z3Q7GK6 7
This final report details a 4-week capsule toxicity study of Perfluorooctane Sulfonic Acid Potassium Salt (PFOS) conducted on Cynomolgus monkeys by Covance Laboratories for 3M, noting compliance with EPA Good Laboratory Practice standards despite a GLP deviation during prestudy procedures. 2002 AR226-1355 QJ2jE242LOJEqBQygVXEQ7oG7 239
This document is a One-Mile Radius Survey and C-8 Sampling Report from August 2002, detailing the results of perfluorooctanoic acid (C-8) analyses in groundwater and surface water in Washington County, Ohio, as part of a consent order involving DuPont and West Virginia environmental agencies. 2002 AR226-1191 pepepeby677Me7ZKDvE9ZpR7D 46
The document is a July 2002 Surface Water Monitoring Report for the Washington Works Facility and local landfills in West Virginia, detailing C-8 (PFOA) analytical results and concentrations in surface water samples. 2002 AR226-1193 15VgrYL1OmzzG09kba0oE3Y8q 50
The document is a Two-Mile Radius Survey and C-8 Sampling Report from the DuPont Washington Works Facility and local landfill in West Virginia, detailing the analysis and results of perfluorinated compound (C-8) sampling conducted between March and May 2002. 2002 AR226-1192 5b3nLD3Baggvvj423RbB01jqN 78
The document is a compilation of historical data on ammonium perfluorooctanoate (C-8) from DuPont's Washington Works main plant and landfills, detailing laboratory analyses and environmental quality assessments as of January 2002. 2002 AR226-1194 gDr381m51yab81dmZQ5KRNBvV 172
The document is a bacterial reverse mutation test report for perfluorooctane sulfonyl fluoride (POSF), sponsored by 3M and conducted by Huntingdon Life Sciences, issued on October 23, 2002. 2002 AR226-1200 rBoyMy7MBaDrK4v3GRQ1we9Vv 42
This document is a report from 3M detailing an in vitro mammalian chromosomal aberration test conducted on perfluorooctanesulfonyl fluoride (POSF) using human lymphocytes, issued on October 22, 2002. 2002 AR226-1201 RwN3ydzBO5JY3M82v6bJ8O78 47
The document is a report from 3M detailing an in vitro mammalian chromosome aberration test conducted on perfluorooctanesulfonyl fluoride (POSF) using human lymphocytes, issued on October 22, 2002. 2002 AR226-1359 omov5yJLZmZnLD2G3L7GYew28 28
The document is a report from 3M detailing a bacterial reverse mutation test for perfluorooctanesulfonyl fluoride (POSF), conducted by Huntingdon Life Sciences, and issued on October 23, 2002. 2002 AR226-1360 QMaDxmm0wZezXaDarbO7gw3y8 29
This document reports on a survey conducted by Entrix, Inc. for 3M, analyzing selected fluorochemicals, including PFOA and PFOS, in water, sediment, and fish samples from the Decatur, Alabama area in 2002. 2002 AR226-1364 pBvNvodBMV6VZZqRv8MD5k8bD 36
The document is a study report by Mark E. Ellefson from the 3M Environmental Laboratory detailing the analysis of samples from the Tennessee River Valley, focusing on perfluorinated compounds, with a completion date of December 17, 2002, and a revised report issued on January 6, 2003. 2002 AR226-1365 qa3V008MQZKLyavj99b1avBaK 285
The document is a final report on a one-generation reproduction study of PFOS conducted in rats, detailing methods, results, and conclusions regarding the effects of PFOS in relation to mevalonic acid/cholesterol challenge and the no-observed-effect level (NOEL). 2002 AR226-1357 ZnV6Mgxrer66v6brG38Y10zJ0 1092
The document discusses changes in the environmental hazard narrative for PFOA, noting a revision in the Margin of Exposure from 300 to 1000, which results in a new drinking water guideline of 10 ug/L, lower than the previously stated 14 ug/L, prompting a need to correct representations made to EPA Region 3 regarding safe drinking water standards. 2002 AR226-1690 O15kbmEVpnN99B03vkX2bZdrQ 1
The document discusses the sharing of a draft monograph related to PFOA by DuPont with regulatory agencies, emphasizing the company's conservative approach in setting its CEG (concentration exposure guideline) and addressing concerns about potential FOIA requests. 2002 AR226-1691 BywMwX1R02MK5O4Yj7daevvBX 1
The document describes the ongoing RCRA interim remedial measures program at the 3M Decatur site, focusing on the construction of a containment structure for an inactive landfill to mitigate groundwater contamination, with key components including a subsurface sheet-piling barrier and an upgraded multilayer cap to prevent precipitation infiltration. 2002 AR226-1700 o9aN2dGjkZo32z5JyRkYg0VxD 1
The document is a December 2002 surface water monitoring report for the Washington Works Facility and local landfills in Washington, WV, focusing on C-8 (PFOA) analytical results. 2002 AR226-1234 zzJDDmV3JNG27XKpRx5nMy1Q7 58
The document reports on a study conducted by Dr. U. Noack-Laboratorium to determine the acute toxicity of a saturated solution of 1-Decanol, 3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro- to zebrafish over 96 2002 AR226-1424 3N5VaEM82m9kqqNp9Bz32xnyD 2
This document from DuPont Engineering details the results of C-8 (PFOA) concentration sampling in public water supplies along the Ohio River, indicating that due to very low concentrations, the frequency of sampling was reduced, with quarterly sampling continuing at three specific locations in West Virginia and Ohio. 2002 AR226-1236 3Q9Jjvr63M4eRDVGxg0Q4JpYn 10
The document is a Two-Mile Radius Survey and C-8 Sampling Report from Washington County, Ohio, detailing the results of C-8 (PFOA) analyses conducted as part of a consent order between DuPont and West Virginia environmental agencies to assess contamination levels. 2002 AR226-1235 j4RknaDE9DKVE4qzbXNzmv0O 121
The document is the Fourth Quarter 2002 monitoring report for surface water and groundwater at the Washington Works facility and local landfills, focusing on C-8 (PFOA) analytical results and environmental assessments in Washington, WV. 2002 AR226-1233 MJ53j2nz4ma7qrqVNRZGwggJ9 170
The document is a report titled "Perfluoroalkylated substances - Aquatic environmental assessment" authored by researchers from the University of Amsterdam and RIKZ, which evaluates the production, use, emissions, and environmental behavior of perfluoroalkyl substances (PFAS) in the Netherlands. 2002 AR226-1237 ExQ7518BR0bMvdzp6KxE1LBjL 100
This document reviews the genotoxicity, carcinogenicity, developmental, and reproductive effects of perfluorooctanoate (PFOA) based on available animal and human studies, concluding that while laboratory studies indicate potential health hazards, these effects have not been observed in worker populations, suggesting PFOA does not present an unreasonable risk to human health. 2002 AR226-1727 np1N8YEVvempn1o3ZOoN17Gk2 23
This document is a revised report prepared by Entrix, Inc. for 3M, detailing a survey of selected fluorochemicals, including PFOA and PFOS, in the Decatur, Alabama area based on sampling conducted in 2002. 2002 AR226-1732 99J8aGaawR1maR9waM9eb0kwL 42
The document discusses air emissions of C8 (PFOA) from the DuPont facility in West Virginia, highlighting that air modeling indicated concentrations above the established screening levels, prompting a response to concerns raised by attorney Robert A. Bilott on behalf of affected Ohio citizens. 2002 AR226-1501 8RnadOeoJvqQqovGDgMJydeVm 3
The document contains E. I. du Pont de Nemours and Company's objections and responses to plaintiffs' discovery requests in a civil action regarding PFOA-related claims in West Virginia. 2002 AR226-1497 NeKv6JyKg572bLBvZMaVnLYQD 70
The document is an Analytical Phase Report for a reproduction study on PFOS conducted by 3M Environmental Laboratory, detailing compliance with GLP standards and noting exceptions in data collection and sample stability. 2002 AR226-1743 4vLg4X907ROZyqM64QvdeJOv1 216
The document is a final report revision from 3M detailing a study (T-6316.9) on fluorochemical levels, specifically PFOS, in naive rats, aimed at identifying sources of contamination contributing to low-level PFOS body burden in control rats from dietary studies. 2002 AR226-1527 XOZXGraM49dvVmrpYQwRpb4pJ 23
This document outlines a protocol for a one-generation reproduction study of PFOS, sponsored by 3M, aimed at investigating the potential protective effects of mevalonic acid and cholesterol against adverse maternal and fetal outcomes previously observed with PFOS exposure in rats, while also defining the no-observed-effect-level (NOEL). 2002 AR226-1206 qkVj9Ry6OdjZGKZQpngznq7OR 1088
DuPont conducted an air dispersion modeling analysis of APFO emissions from its Washington Works facility in Parkersburg, West Virginia, for the year 2002 to predict long-term ambient air concentrations based on actual plant emissions. 2002 AR226-1539 mLp0QeLzNVkxom3M6zXmrO0Q 8
DuPont conducted an air dispersion modeling analysis of APFO emissions from its Washington Works facility in Parkersburg, West Virginia, for the period of September 2002 through August 2003 to predict long-term ambient air concentrations resulting from actual plant emissions. 2002 AR226-1540 b5o3bKay1nJxyBkarLqNx6XG3 8
The document is an analytical phase report for a reproduction study on PFOS conducted with the Northern Bobwhite by 3M Environmental Laboratory, detailing compliance with TSCA GLP standards and noting exceptions in data collection and stability assessments. 2002 AR226-1754 RJ9edq2Eg17dakV6aO1xK7gyV 226
The document presents blood data from DuPont employees for the year 2001, including levels of perfluorinated compounds, with specific results for Granular Polykettle Operators and Fine Powder/Dispersion Autoclave Operators, while maintaining employee confidentiality. 2002 AR226-1638 xznwKB6ob74QgGO3E8v1MBLDm 1
The document discusses a conference call to review the results of a groundwater investigation related to perfluorinated compounds at the Shimizu Works site, specifically focusing on sampling from eight remediation system pumping wells. 2002 AR226-1671 a45DYoOMy3bNLVo2D00gJZO1b 13
The document reports on a study conducted by 3M Company to assess the acute oral toxicity of a material identified as T-2001CoC in male and female albino rats, finding an LD50 between 0.5 ml/kg and 2.5 ml/kg, with significant effects observed at higher dosage levels. 2001 AR226-0217 daxp3rd61moN2aZ67526bw5a9 2
The document reports on a primary eye irritation study conducted by 3M Company on a test material (T-2001CoC) using albino rabbits, concluding that the material is not a primary ocular irritant but requires cautionary labeling. 2001 AR226-0218 4aJgwG2Ypkoe6rawoqxz5xoMa 3
The document details a primary skin irritation study conducted by 3M Company on a material related to PFOA, using albino rabbits to assess the degree of irritation caused by the substance when applied to intact and abraded skin. 2001 AR226-0219 wg7Kw9rXzeVMXKG0nxROdQ4GQ 3
The document is an analytical report from 3M Environmental Laboratory detailing a 104-week dietary carcinogenicity study on rats, which measured the presence and concentration of PFOS and related compounds in serum and liver samples after exposure to N-Ethyl Perfluorooctanesulfonamido Ethanol. 2001 AR226-1068 5kjGjLZ8R999MgvEvpLjG5zV 310
The document is an analytical report from the 3M Environmental Laboratory detailing the presence and concentration of PFOS, PFOSA, PFOSAA, EtFOSE-OH, M556, and PFOSEA in serum and liver samples from rats exposed to N-Ethyl Perfluorooctanesulfonamido Ethanol as part of a 104-week dietary carcinogenicity study. 2001 AR226-1068 jmyMy67DgDJ938d6LVeGprJYO 212
3M is on track with its phase-out plan for certain PFOS derivatives, having ceased production in multiple categories as of December 31, 2000, while also meeting reduced production goals for extended use categories. 2001 AR226-0997 qmKYM2E5OjnLbGG01vL63Vodj 1
Unreadable document. 2001 AR226-1001 82bnKkrXnQ0z9aB0G89npYg7o 2
DuPont's January 25, 2001 letter to the EPA reports the results of blood serum tests for Ammonium Perfluorooctanoate (APFO) among workers, revealing a maximum concentration of 9.0 ppm and a mean concentration of 1.53 ppm, with an investigation ongoing into elevated levels found in a specific job group. 2001 AR226-1000 Gmk4eEvRREgxKGNJ91Q1x7NbV 14
The document is a correspondence from the EPA requesting DuPont Haskell Laboratory to provide the complete data set of blood concentrations related to Ammonium Perfluorooctanoate (AFPO) as summarized in their report. 2001 AR226-1003 pe1q28jEvRoQNNaXvL5OGK38j 1
The document is a note summarizing a meeting held on January 4, 2001, between the EPA and the Department of Defense regarding alternatives to PFOS-based Aqueous Film Forming Foam (AFFF) and potential plans for transitioning away from its use. 2001 AR226-1004 ZJmneQpZx95801jn5ReoVL050 2
The document summarizes a presentation by toxicologist Rich Purdy to the EPA on March 26, 2001, discussing the relative toxicity and environmental presence of perfluoroalkanoic acids, specifically highlighting that perfluorooctanoic acid (PFOA) is less bioaccumulative and toxic compared to perfluorooctane sulfonate (PFOS), with low levels 2001 AR226-1005 7OyOYBkk58X7N2ozmGp0Y9mmR 15
The document discusses the EPA's substantial data on perfluorooctyl sulfonates (PFOS), specifically related to 3M's "Light Water" AFFF formulations, and outlines the ongoing rulemaking activity regarding a proposed significant new use rule (SNUR) for 90 PFOS chemicals being discontinued by 3M Corporation. 2001 AR226-1006 Z8q10qjkYXvEoGvNQOb52vqO 2
The document summarizes a March 7, 2001 meeting between the EPA and the Fluoropolymer Manufacturing Group, where concerns were raised about the discontinuation of ammonium perfluorooctanoate (APFO), a derivative of perfluorooctanoic acid (PFOA), by 3M, and the ongoing toxicology research and regulatory considerations regarding APFO and 2001 AR226-1007 Gzz7v2EJ0GL1322bq938m9rZ7 1
The document is a facsimile transmittal from Allen C. Weidman of The Society of the Plastics Industry, Inc. to the EPA, clarifying the status of submissions related to Confidential Business Information (CBI) and non-CBI presentations concerning PFOA made by the Fluoropolymer Manufacturers Group. 2001 AR226-1008 ybYE9DZ5NjaQVQMV9LkNpe3Y2 1
The Fluoropolymer Manufacturers Group provided the EPA with presentation slides detailing their toxicology program, which includes a bio-monitoring test protocol and discussions on alternatives to fluorinated compounds used in manufacturing. 2001 AR226-1009 Gzr3q0QBG3kMBnnMarXr0GmJ7 1
The document outlines the agenda and objectives of an EPA meeting with the Fluoropolymer Manufacturers Group (FMG) on March 7, 2001, focusing on the toxicology program, mass balance data, and industry commitments regarding the safe use and environmental impact of fluoropolymer processing aids (FPAs), including perfluorooctanoic acid (APFO) and perfluor 2001 AR226-1010 3ekmejp06BVk2ybgOvDMD4eqn 19
The document is a note summarizing a meeting held on March 28, 2001, between the EPA and 3M to discuss the status of 3M's testing program, phase-out plan for PFOS, and related OECD activities. 2001 AR226-1013 Y99Vddj6r8d0Ywq4LQgq9KYD 1
The Fluoropolymer Manufacturers Group expresses appreciation to the EPA for ongoing discussions regarding fluoropolymers and APFO, providing presentation materials that include both confidential and non-confidential information related to the manufacturing processes and benefits of fluoropolymers. 2001 AR226-1012 6R9wjk1oEJq8ZyYYR0v0bbZX9 50
3M provided an update to the EPA regarding their ongoing study of the serum half-life of perfluorooctane sulfonate (PFOS) in retired workers, indicating that new data from a larger group of 27 employees suggested a half-life of approximately 303 days, which is an improvement over previous estimates but still requires cautious interpretation due to study limitations. 2001 AR226-1015 7MRXLDNOvgd1rLLM6mJokO5be 2
3M submitted a TSCA 8(e) notice to the EPA detailing acute toxicity studies on perfluorooctane sulfonate (PFOS) conducted on honey bees, reporting a contact LD50 of 59.7 mg/Kg (moderately toxic) and an oral LD50 of 5 mg/Kg (highly toxic). 2001 AR226-1016 3N7yKN6DbO2VB0GxLyey7wdqn 1
3M submitted a TSCA 8(e) Supplemental notice to the EPA detailing analyses of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) in human serum samples from various age groups, revealing specific concentration levels and ranges for these compounds. 2001 AR226-1019 oD0n8jNymbxZ5w0kM079Bajwg 2
The document discusses a conference call on March 19, 2001, regarding new findings from a serum half-life study on PFOS conducted by 3M, which indicated a half-life of approximately 303 days among 27 retired employees, an improvement over earlier estimates based on limited data from only 3 workers. 2001 AR226-1020 QpRkJ12Dm5QvZrLEOBgEZM57 2
3M submitted a supplemental notice to the EPA regarding a two-year dietary study of N-ethyl perfluorooctanesulfonamidoethanol (N-EtFOSE), highlighting statistically significant findings of thyroid follicular-cell tumors in male rats, in addition to previously reported hepatocellular adenomas in female rats. 2001 AR226-1021 zQwbmMVZjZOqwMwKVvx61JvBB 2
3M submitted a TSCA 8(e) substantial risk notice to the EPA regarding preliminary findings from a two-year dietary study on potassium perfluorooctanesulfonate (PFOS) in rats, indicating that the data may meet reporting thresholds, while noting that the final report will provide further interpretation of biological significance. 2001 AR226-1022 3JBpq8Jk4qEqd5oKZqXbzYQbn 2
This document from DuPont Haskell Laboratory provides a corrected dataset of blood concentrations of ammonium perfluorooctanoate (APFO) in employees, responding to a request from the EPA and highlighting errors found in a previous report. 2001 AR226-1023 Gmn1mEqBxyY43Md1rRp3DoDZ4 4
This document outlines ongoing research protocols by 3M and Johns Hopkins University to identify and analyze levels of various fluorochemicals, including PFOA and PFOS, in the sera of children in the United States, with final reports due in 2001 and 2004. 2001 AR226-0019 1LY025q30LdVKjXRGOk3D9Lo 4
3M reported on the ongoing serum half-life study of perfluorooctane sulfonate (PFOS) in retired workers, revealing that the mean serum half-life for 18 of 27 employees was approximately 303 days, which is an improvement over previous estimates but still presents interpretive challenges. 2001 AR226-1024 06g0jJ1GRDK0mMMB4aw3VxwRd 2
The document is a letter from the EPA to DuPont Haskell Laboratory requesting clarification on why the results of human blood serum tests for ammonium perfluorooctanoate (PFOA) were submitted as voluntary rather than under TSCA Section 8(e), given potential human health hazard concerns. 2001 AR226-1025 O1aemwdmGdw26qD7193oz7Mvj 1
This letter from DuPont Haskell Laboratory responds to an EPA inquiry regarding exposure and health effects related to PFOA, indicating that no adverse health effects have been found among exposed employees, and referencing similar findings from studies by 3M. 2001 AR226-1026 a1e4J1OpVJnggvR8XQQkr8Q59 2
3M submitted a TSCA 8(e) supplemental notice to the EPA correcting chemical descriptions for sulfonate-based and carboxylic-based fluorochemicals, including perfluorooctane sulfonate, based on analyses of individual human sera samples collected in 1995. 2001 AR226-1027 YGam68vJ3757b3wNGy8N8G9Dy 4
3M Company is requesting the U.S. EPA to redesignate three studies related to fluorochemicals, including a range finding rat teratology study and two eye irritation studies, to the TSCA Section 8(e) docket, as they supplement previous submissions concerning the health effects of these compounds. 2001 AR226-1028 gbYpoE5Q2GV7794NE69QO7gYL 2
3M submitted a TSCA 8(e) Supplemental notice to the EPA reporting completed analyses of sulfonate-based and carboxylic-based fluorochemicals, including perfluorooctane sulfonate, in individual stored human sera. 2001 AR226-1029 wqNRZ98aMjqKgwdekv2eJkjg4 3
3M submitted a compact disc to the EPA containing new and previously unsubmitted studies on perfluorooctane sulfonates and related compounds, as part of their ongoing dialogue regarding fluorochemicals. 2001 AR226-1030 xdy1JYRMqYqK9yB864aKRVb80 4
The document is a letter from the EPA to 3M Company regarding the submission of information on perfluorooctane sulfonates (PFOS) and related compounds, confirming its inclusion in the TSCA Public Docket as part of the administrative record on PFOS. 2001 AR226-1031 RaJJv0RezR80OEpvpnLO9e1xk 1
This document appears to be a presentation or informational material from the Fire Fighting Foam Coalition discussing Aqueous Film Forming Foam (AFFF), its types, applications, and market segments, with a focus on its effectiveness in fire suppression and safety. 2001 AR226-1032 r6pOB9awyzdKRd70OpyEmy5pr 36
DuPont Chemical Solutions Enterprise submitted sanitized copies of two presentations regarding their Research Programs on PFOA and telomer compounds to the U.S. EPA on September 24, 2001, ensuring that no confidential business information was included. 2001 AR226-1033 jgdbGqzmXbV0Gq5p4oaqmbYB9 44
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports and analytical data on sulfonate-based fluorochemicals, specifically detailing blood serum and liver levels of PFOS and related compounds from previous studies. 2001 AR226-1035 mmNoJg7dZXgoDB8e66b13ad1g 3
The document is a correspondence from DuPont to the U.S. EPA, providing sanitized copies of two presentations regarding their research programs on perfluorinated compounds, specifically mentioning updates on the DuPont Research Program and Telomer Research Program, both presented on February 21, 2001. 2001 AR226-1034 e5zg18Qj8Y0Dn1ann3jNdrjjm 26
3M submitted a TSCA Section 8(e) Supplemental Notice to the EPA, providing final reports and analytical data on sulfonate-based fluorochemicals, including PFOS, to facilitate access to information related to previous notifications. 2001 AR226-1037 g2DdJ01J7oBDM9zmLv2XLJ8MQ 9
3M is submitting final reports and supplemental information related to previous TSCA Section 8(e) notifications regarding sulfonate-based fluorochemicals, including analytical studies on PFOS and its derivatives in blood serum and liver levels from rat studies. 2001 AR226-1038 reqgyBn11y4540pmNKVpwyjJ 13
This is a 3M letter addressed to the Section 8(e) Docket Coordinator regarding a TSCA 8(e) Supplemental Notice on sulfonate-based fluorochemicals, listing attached submissions related to previous notifications. 2001 AR226-1036 ppEbgmwOReNLGydvwa9Ev1de6 96
This document outlines a study by 3M to determine the concentration ratios of perfluorooctanesulfonate (PFOS) in human liver, serum, and bile, with the aim of understanding tissue concentrations and their significance, following ethical guidelines for tissue procurement. 2001 AR226-0021 g2e0ew9Yvbaqn9qgQmJJvY74G 3
This document is a meeting agenda for a DuPont Telomer meeting scheduled on December 17, 2001, from 1:00 to 3:00 PM, listing participants and their organizations. 2001 AR226-1041 EqY1VpEzX6pXoaBLMeQe7b5k4 2
3M is submitting final reports and supplemental information related to previous TSCA Section 8(e) notifications, including analytical studies on the presence and concentration of PFOS and other sulfonate-based fluorochemicals in the liver and serum of rats exposed to NEtFOSE. 2001 AR226-1039 oKJrkqgL3EqZLMZZ1VypVzbr 41
This is a cover page for a Telomer Research Update Meeting scheduled for December 18, 2001, with no analytical content retained in the OCR. 2001 AR226-1043 1Q1wnrmzmQeZb1Z15Omq0emvj 2
The document is a status report on the Telomer Research Program related to perfluorinated compounds, summarizing key events and updates on toxicology, environmental fate, and effects as discussed in meetings throughout 2001. 2001 AR226-1044 dQEvBVx10VgaJMmp6Y1ZkONee 33
The document is a DuPont Product Stewardship Update discussing various aspects of fluorotelomer products, including their chemical properties, toxicology studies, and environmental effects related to perfluorinated compounds. 2001 AR226-1042 5kqLDKyjD1GyGb2MObwK5oK50 35